RNA

Conviction 9HealthcareScan · Mon, Aug 10, 2026

RNA$12.24-0.81%

ResistanceSupportVol 14

Vol MA14 122.38K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Atrium Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.aviditybiosciences.com ↗

Price12.24

Change-0.81%

Gap-0.28%

Rel volume1.44×

Avg volume134.16K

Avg $ vol1.6M

SMA 2011.84

SMA 5012.34

SMA 20038.13

Price vs 50-0.82%

Price vs 200-67.90%

MA stackbearish

50/200 cross—

Supertrenddown · 12.59

RSI (14)53

MACD hist0.11

MACD crossbull · 2d

Stoch %K / %D82 / 84

ADX (14)25

+DI / −DI20 / 16

RSI divergence—

MACD divergenceBullish

ATR %+3.44%

ADR %3.17%

52w high72.93

52w low11.18

From 52w high-83.22%

Above 52w low+9.48%

New 52w highNo

SqueezeOff

Bollinger width12.77%

%B0.76

Donchian pos81.92%

Donchian high12.49

Donchian low11.13

AVWAP (52w high)45.98

vs AVWAP high-73.38%

AVWAP (52w low)11.78

vs AVWAP low+3.95%

OBV trendFlat

Chaikin MF (20)-0.15

Today vs 20d1.44×

Avg vol (14d)122.38K

Avg vol (20d)134.16K

Avg $ vol (20d)1.6M

Market cap—

RS 3m (vs SPY)-10.48%

RS 6m (vs SPY)-95.72%

RS line new highNo

Trend template0/8

Technical rank18.8

1 week+8.03%

1 month-1.77%

3 months-6.35%

6 months-83.19%

1 year-74.64%

YTD-83.02%

P/E—

P/B0.90

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current13.04

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-56.94M

Revenue19.64M

Net income-16.63M

Gross profit—

Free cash flow—

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out17.11M

Employees391

ListedFri, Feb 27, 2026

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction9 / 100

Pattern quality—

Tech rank18.8 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance13.80

Support11.37

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RNA

All disclosures →

No recent disclosed trades by Congress in RNA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RNA · 10 buys

Insider	Side	Shares	Value	Traded	Filed
Kenney Stephanie See Remarks · Common Stock · 2026-04-20	Grant	30K	$0	2026-04-20	2026-04-22
Hughes Steven George Chief Medical Officer · Stock Option (Right to Buy) · 2026-04-20	Grant	60K	$0	2026-04-20	2026-04-22
Kenney Stephanie See Remarks · Stock Option (Right to Buy) · 2026-04-20	Grant	60K	$0	2026-04-20	2026-04-22
Hoyos Rocio Martin Chief Strategy Officer · Common Stock · 2026-04-20	Grant	30K	$0	2026-04-20	2026-04-22
Winslow Brendan R. Chief Financial Officer · Common Stock · 2026-04-20	Grant	30K	$0	2026-04-20	2026-04-22
Gallagher Kathleen P. See Remarks · Stock Option (Right to Buy) · 2026-04-20	Grant	205K	$0	2026-04-20	2026-04-22
Hughes Steven George Chief Medical Officer · Common Stock · 2026-04-20	Grant	30K	$0	2026-04-20	2026-04-22
Winslow Brendan R. Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-20	Grant	60K	$0	2026-04-20	2026-04-22
Gallagher Kathleen P. See Remarks · Common Stock · 2026-04-20	Grant	102.5K	$0	2026-04-20	2026-04-22
Hoyos Rocio Martin Chief Strategy Officer · Stock Option (Right to Buy) · 2026-04-20	Grant	60K	$0	2026-04-20	2026-04-22

SEC filings

EDGAR filings in RNA · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.